AC 100

Drug Profile

AC 100

Alternative Names: AC-100; Dentonin; DTN

Latest Information Update: 28 Jul 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Acologix
  • Class Osteoporosis therapies; Peptide fragments
  • Mechanism of Action Dinoprostone modulators; Osteogenesis stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes - Bone disorders; Cartilage disorders; Periodontal disorders

Highest Development Phases

  • Discontinued Bone disorders; Cartilage disorders; Periodontal disorders; Postmenopausal osteoporosis

Most Recent Events

  • 06 Mar 2010 AC 100 is still available for licensing (
  • 06 Mar 2010 No development reported - Phase-I for Postmenopausal osteoporosis in USA (SC)
  • 06 Mar 2010 Phase-I clinical trials in Bone disorders in USA (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top